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Summary The ABO(H) and Y antigen status of epithelial cells from 45 breast carcinomas, 14 benign breast
lesions and 7 normal breasts have been assessed using an indirect immunoperoxidase histochemical assay and
a series of blood group specific monoclonal antibodies. All 20 A, AB and B group tumours had lost the A
and B isoantigens, 13 of these tumours were however found to express H and Y antigens. Of 25 group 0
tumours 17 expressed the expected H and Y antigens. These findings were not dependent on the histological
nature or the invasive characteristics of the tumour. Similar results were obtained when 28 metastases from
breast carcinomas were examined, the H and Y antigens being identified in the tumour elements in 24 lymph
nodes while we failed to identify either the A or B antigens. The development of breast malignancy appeared
therefore to correlate best with the deletion of A and B glycosyl transferases. Normal breast tissue
consistently expressed the expected blood group isoantigens. Areas of benign breast disease showed a more
varied pattern of antigen expression. Seven of 14 lesions lacked ABH antigens, the loss of blood group
structures could not however be correlated with any specific histological features and was not limited to the
loss of A and B substances.
The studies of Szulman (1960, 1962a,b, 1964) and
Hakomori (1981) have already established a link
between ontogenesis, oncogenesis and A, B and H
antigen expression. Immunohistochemical studies
by a number of groups have demonstrated that the
development of carcinomas within a number of
organs including lung (Davidson & Ni, 1969),
cervix (Davidson et al., 1969) and prostate (Gupta
et al., 1973) have been associated with the loss of A
and B isoantigens. We have simultaneously
reported work that suggests that the deletion of
ABO(H) blood group isoantigens (BGIs) that has
been previously described within prostatic
epithelium following malignant transformation is
largely limited to a deletion of the A and B
isoantigens (Vowden et al., 1985). This disagrees
with the previously stated findings of Gupta et al.
1973, who found a loss of all these antigens. Recent
reports by Strauchen et al., (1980), and by Shull et
al. (1981) have suggested that BGIs are lost from
malignant breast epithelium. Both these groups
have, however, relied upon the specific red cell
adherence test and have used similar reagents to
those employed by Gupta et al. (1973) to isolate
BGIs. Strauchen and associates have also suggested
that the early loss of A and B BGI expression in
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some histologically benign lesions supports a
possible link between fibrocystic disease and
mammary carcinoma (Strauchen et al., 1980).
In the light of our results on BGI expression in
prostatic tissue we have reinvestigated ABO(H)
antigen expression within normal breast tissue,
benign breast disease and a variety of histological
types and grades of breast carcinoma using a series
of blood group specific monoclonal antibodies
(McAbs) and an indirect immunoperoxidase
staining technique on paraffin-embedded formalin-
fixed material.
Material and methods
Histological material
As in our previous study formalin-fixed paraffin-
embedded specimens were obtained from the
Pathology Department, Addenbrooke's Hospital,
Cambridge, UK. The histological distribution of
the material chosen and the associated patient
blood group are given in Table I. Where possible
material was selected to include both normal and
abnormal epithelium from the same subject. In all
59 specimens were examined, 14 from specimens
showing benign breast disease and 45 from biopsies
or mastectomy specimens showing varying degrees
of invasive and in situ malignancy. Lymph node
metastases were available for examination from 22
of the 39 invasive carcinomas, multiple nodes
containing metastases being available in 15 of the
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22 specimens. A further 6 lymph nodes were
examined from late axillary node metastases
occurring a variable number of years following
mastectomy, all these patients had received
radiotherapy.
Monoclonal antibodies
Again as in the previously reported study six mouse
derived McAbs with known blood group substance
specificity were used.
Anti-A (Al5/3D3.92.1) and anti-B
(NB1/19.112.28) McAbs were obtained from the
MRC Laboratory of Molecular Biology,
Cambridge. The specificities of these McAbs and
their use as immunohistochemical reagents have
been described elsewhere (Voak et al., 1982; Lowe
et al., 1983; Finan et al., 1983).
We employed the same three anti-H McAbs used
in our earlier study. Two McAbs, 101 and 102,
were kindly provided by Dr Pastan (Laboratory of
Molecular Biology, National Cancer Institute,
Bethesda, Maryland, USA). Characterisation of
these McAbs has shown that 102 specifically binds
to a Type 2H structure (Fredman et al., 1983;
Richert et al., 1983), while 101 McAb probably
binds to both a Type 1 and 2 antigen (personal
communication from Dr Pastan). As previously,
both McAbs were used at a dilution of 1: 75 in PBS
(Dulbecco's 'A' tabs: Oxoid Ltd., Basingstoke,
UK). An additional comparison was made with a
commercial anti-H mouse McAb (Dako
Corporation, USA). This McAb was used at the
suggested dilution of 1 in 20.
F-3 McAb with the Y-antigen was kindly
provided by Dr K.O. Lloyd (Memorial Sloan-
Kettering Cancer Centre, 1275 York Av., New
York, NY 10021.). This monoclonal has been
shown to have specificity for the difucosyl Type 2H
structure, the Y antigen (Lloyd et al., 1983). In this
study a sample of ascitic fluid was diluted 1: 150 in
PBS.
Optimal dilutions for all these McAbs has
already been established being defined as the
concentration that produced the maximum staining
of endothelial and red cell elements with acceptable
(or absent) non-specific background staining. All
McAbs contained 0.1% azide and were stored at
-20°C. Those samples in current use were kept at
40C.
Immunoperoxidase technique
The use of McAbs in an indirect immunoperoxi-
dase technique has been described elsewhere (Finan
et al., 1982a,b) and has been outlined in our earlier
paper. Mounted slides were viewed under an
Olympus CH microscope and photographed onto
KB14 film (ASA 20). The controls included in this
study were identical to those we documented in our
report on BGI expression with the prostate
(Vowden et al., 1986).
Results
Normal breast tissue, whether obtained from a
pathological or non-pathological source,
consistently displayed BGIs. Duct epithelium was
found to express the expected antigens in all 66
specimens examined. In contrast in the majority of
normal lobules BGIs were only weakly expressed
and in most only isolated acini displayed staining.
There was, however, considerable variation in the
intensity of staining seen between specimens and
also a marked variation in staining seen between
individual acini within any one specimen. Figure la
shows the pattern of staining observed in an area of
normal breast tissue taken from a breast containing
an invasive scirrhous carcinoma. In all cases
erythrocytes and vascular endothelium were found
to stain for the expected blood group, those from
group A and B subjects also staining for both the
H and Y isoantigens.
In specimens from areas of benign breast disease
(both fibrocystic and fibroadenomatous) BGI
expression was found to be more varied. BGIs were
detected in 50% of specimens (7 of 14, see Table I).
Antigen positive specimens showed no obvious
histological difference from antigen negative ones.
It was of interest that the loss of BGIs from these
specimens was generally associated with the loss of
all BGIs as opposed to the loss of A and B
isoantigens which was the most common finding in
malignant breast epithelium. Within cysts the whole
epithelium was either antigen positive or negative,
the staining of cyst debris following the pattern
established by the cyst epithelium. This variation
may be related to secretor status but this was not
examined in this study.
Table I Histological material and blood groups
Blood groups
Tissue specimens A B AB 0
Normal 3 1 0 3
Fibrocystic disease 2 1 0 2
Fibroadenomata 5 0 0 4
In situ carcinoma 2 1 0 3
Invasive carcinoma 11 5 1 22
Metastatic carcinoma 14 1 1 12ABH AND Y ISOANTIGENS IN THE BREAST 315
Fig. l(a) Fig. 1(b)
Fig. 1(c) Fig. 2
Figures la-c These represent sections from a mastectomy specimen from a blood group A subject. In (a) an
area of normal breast epithelium is shown stained with A15/3D3.92.1, an anti-A McAb. Note the varying
intensity of staining shown by the acini and the staining of blood vessels. Contrast this with (b), also stained
with A15/3D3.92.1 McAb, where the tumour epithelial elements have failed to stain but blood vessels are
clearly outlined. Compare this with (c) which illustrates the same tumour stained for the H isoantigen with
102 McAb. Note the marked variation in staining and the often intense staining of individual cells in this
section. Some tumour cells are however antigen deficient. (a) x 100; (b) x 200; (c) x 200. Counterstained with
haemaemalum.
Figure 2 This section illustrates the intense staining seen in an axillary metastasis invading fat. The section is
from a group 0 subject stained with E-3 McAb. x 200. Counterstained with haemalum.
Breast malignancy was found to be consistently
associated with the loss of A and B BGIs in all 20
group A, AB and B tumours examined, this finding
being repeated in all blocks from each specimen
(Table II). Non-neoplastic tissues from the same
specimens were, however, antigen positive. The
contrast may be seen by comparing Figures la and
lb which show benign and malignant tissue from
the same group A patient stained with
A15/3D3.92.1, the anti-A McAb. Of these 20
tumours, 13 were found to express both H and Y
antigens. Figure lc illustrates the expression of the
H isoantigen by the same group A tumour
illustrated in Figures la and lb. The preservation
of the H and Y antigens was independent of the
histological grade of the tumour or its invasive
nature. The staining intensity though an unreliable
guide would seem to indicate that where detected
the H and Y BGIs were present in significant
quantities.
Of the 25 group 0 tumours 17 stained with F-3
and 102 McAbs indicating that a Type 2 chain
structure is represented in these tumours (Table II).
Again histological grade and invasive nature
appeared to have no influence on antigen status.
The staining patterns seen in many specimens have
served to emphasize the heterogeneous nature of
the tumour cell population, though this may in part
reflect a tissue processing artefact.
The BGI status of metastatic breast tumour cells
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Table II Staining characteristics of normal, benign and malignant breast
tissue
Monoclonal antibodies
Bloodgroup No. A15/3D3 NBJ/19 Dako H 101 102 F-3
Normal breast tissue
A 3 3 0 3 3 3 3
B 1 0 1 1 1 1 1
O 3 0 0 3 3 3 3
Fibrocystic disease
A 2 1 0 1 1 1 1
B 1 0 0 0 0 0 0
O 2 0 0 1 1 1 1
Fibroadenomata
A 5 2 0 3 3 3 3
B 0
O 4 0 0 2 2 2 2
In situ carcinoma
A 2 0 0 1 1 1 1
B 1 0 0 1 1 1 1
O 3 0 0 2 2 2 2
Invasive carcinoma
A 11 0 0 4 5 7 7
AB 1 0 0 1 1 1 1
B 5 0 0 2 2 3 3
O 22 0 0 12 13 15 15
Metastatic carcinoma
A 14 0 0 10 10 12 12
AB 1 0 0 1 1 1 1
B 1 0 0 0 0 0 0
O 12 0 0 9 9 11 11
Numbers in McAb columns indicate specimens staining for BGIs.
simply reflected the antigen status of the primary
tumour in the 22 specimens in which primary and
metastatic material was available. Of the 28
specimens of metastatic breast malignancies
examined 24 lymph nodes were found to contain
tumour cells which stained with 102 and F-3
McAbs (Table II), Figure 2 showing the typical
staining seen in a metastatic deposit in axillary fat.
Of the 15 specimens with multiple lymph node
metastases 11 had at least one node showing
staining for BGIs. In all but 3 of these cases both
antigen positive and negative tumour metastases
were present, a finding that simply reflected the
variability of antigen expression within the primary
growth. Of the 6 biopsy specimens from late lymph
node recurrences 4 contained tumour cells
expressing both H and Y BGIs.
Control slides all showed the expected pattern of
staining, no inappropriate BGIs being identified.
Discussion
Szulman (1962) found the pattern of BGI
expression within the breast interesting, for even in
normal breast tissue the epithelial elements showed
extremely irregular BGI expression. The picture of
antigen expression not only varies from lobule to
lobule but also within lobules where ductules and
acini containing BGIs were found adjacent to
antigen deficient structures. Non-secretors were
found to express little or no blood group antigen.
A similar pattern of BGI expression has been
reported by Strauchen et al. (1980). This group
reported that duct epithelium was strongly positive
while normal lobules only weakly expressed A and
B antigens, the pattern of antigen expression being
the same whether the material was obtained from
pathological or non-pathological biopsies.
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material and an identical technique to that
employed by Strauchen (1962) found normal breast
tissue to be BGI deficient. The results obtained in
the present study are in broad agreement with those
of Szulman (1962) and Strauchen et al. (1980). We
are unable to comment on the role of secretor
status on antigen expression, but it may be that
secretor status is responsible for some of the
variation in antigen expression which we have seen.
The majority of studies have detected BGIs in
benign breast lesions (Szulman, 1962; Tellem et al.,
1963; Shull et al., 1981), Strauchen has however
reported a reduction in BGIs in cysts, duct
hyperplasia, sclerosing adenitis and duct
papillomatosis. In the present study BGIs have
been found to be reduced and occasionally absent
from areas of fibrocystic disease and
fibroadenomata.
Of the earlier studies two have failed to identify
BGIs in any breast malignancy including in situ
carcinomas (Strauchen et al., 1980; Shull et al.,
1981). Strauchen and associates did not include
group 0 patients in their series or look for the H
antigen in group A and B specimens because of
difficulties with the plant lectins used to label the H
antigen. Shull et al. though including group 0
patients used only anti-sera specific for the patients'
blood type and thus failed to search for H antigen
in over half his series. These facts may explain
some of the differences between our results and
those reported in these earlier studies, for though
we failed to demonstrate the A and B isoantigen in
any tumour the H and Y isoantigens were
demonstrated in 27 of 38 invasive and 5 of 6 in situ
carcinomas independent of the patients' blood
group.
It is interesting that although our findings that A
and B isoantigens are lost following malignant
transformation agree with those of Shull et al.
(1981) and Strauchen et al. (1980) it differs from
those reported by Tellem et al. (1963). This group
detected A and B antigens in 50% of acetone fixed
cryostat sections. Two possible reasons exist for
this disparity. Firstly the latter authors examined
fresh material while others, including ourselves,
have relied on paraffin-embedded formalin-fixed
specimens. It would be difficult to accept this as a
cause of the disparity in results as we have
successfully demonstrated H and Y isoantigens in
paraffin-embedded material. The only difference lies
in the labelling techniques. Tellem et al. used a
direct technique with fluorescent labelled human
hyperimmune polyclonal anti-sera while we have
used a two stage indirect immunoperoxidase
technique with McAbs. It is possible that the
greater potential specificity of McAbs as compared
with polyclonal anti-sera may explain the disparity
between observed results, cross reacting
components of the polyclonal anti-sera producing
artefactual staining. Alternatively the theoretical
enhancement with polyclonal anti-sera may have
revealed a low level expression of A and B
isoantigens.
The pattern of antigen expression we have found
is very similar to that we have seen in the prostate
(Vowden et al., 1986), the only difference being in
the staining seen with 101 McAb which was far
more intense in breast tissue. The staining with 102
and F-3 McAbs certainly indicate that a Type 2
structure is present in neoplastic breast epithelium.
The apparent loss of A and B structures would
suggest that both A and B glycosyl transferases are
reduced or absent in these malignancies, a finding
offering support to the enzymatic studies of Stellner
et al. (1973) and Kim & Isaacs (1975). Springer et
al. (1975, 1979) have demonstrated that precursor
cryptic antigens of the MN blood group system, the
T and Tn antigens, are revealed in the majority of
breast tumours. A certain similarity exists between
these findings and those reported here as the H
antigen is the 'non-cryptic' precursor of both the A
and B antigen.
Studies other than that of Tellem et al. (1963)
have not commented on the antigen status of
metastatic lesions. From the results report here it
would appear that the great majority of breast
carcinoma metastases are H and Y BGI positive
and exhibit similar staining to the primary tumour.
As may have been expected just as the primary
tumour contained both BGI positive and BGI
negative zones so the metastases could exhibit
similar variability. This finding contradicts
Davidsohn's (1972) statements on antigen loss and
metastatic potential but agrees with the findings of
Tellem et al. (1963) that antigen loss within primary
tumours was not associated with an increase in
metastatic potential.
Several reports have occurred in the literature
suggesting that BGI expression by neoplastic cells
may change following radiotherapy (Alroy et al.,
1978; Wolk & Bishop, 1983). In both these studies
blood group antigen negative transitional cell
carcinomas of the bladder were found to have
reacquired these antigens following radiotherapy.
These changes may simply reflect the heterogeneity
of the tumour population. It has been suggested
that these changes may indicate 'redifferentiation'
of the tumour cells following radiotherapy.
Contradictory evidence has been produced by
Richie and Yap (1981). They report no changes in
blood group antigen status following radiotherapy.
The findings in the present study would tend to
support this as in the 6 metastatic lymph nodes
examined from post-radiotherapy patients the318 P. VOWDEN et al.
antigen status paralleled that seen in the non-
radiotherapy nodes. There was certainly no
reacquisition of either A or B BGIs in the three
group A or the group B derived nodes.
Results reported here and in our concurrent
studies on the prostate (Vowden et al., 1986) have
only served to emphasize the marked cell to cell
variation in BGI expression that occurs. This may
represent changes in antigen expression by cells at
different stages of the cell cycle. Though no
evidence has been offered here to support this
statement other workers have supported this theory
(Hogman, 1960; Pann & Kuhns, 1972). In fact
Hogman has postulated that the capacity to
produce BGIs may be lost during cell division.
Dabelstein and Fejerskor (1974) have produced
data supporting this, documenting the loss of blood
group antigens in healing oral epithelium. Changes
in the cell membrane glycolipids during cell division
have been described (Hakomori, 1981) and may be
responsible for the overall change in antigen
expression.
To conclude, we have documented the presence
of BGIs in normal breast tissue and in the majority
of benign breast lesions. In contrast to other studies
we have found that although malignant
transformation is associated with a loss of both A
and B isoantigens the H and Y BGIs are
maintained in the bulk of tumours.
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